Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock with an IPO date in 2021, returning 12,482.3%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 12,482.34% |
Oncology Institute (TOI) | 1,138.56% |
BT Brands Inc Warrant (BTBDW) | 706.64% |
TMC the metals (TMC) | 679.39% |
Protagenic Therapeutics (PTIXW) | 669.23% |
Oklo (OKLO) | 593.17% |
OneMedNet (ONMDW) | 539.94% |
ThredUp (TDUP) | 499.31% |
Dave Inc Warrants (DAVEW) | 480.89% |
IREN (IREN) | 479.73% |
Thayer Ventures Acquisition (TVACW) | 461% |
Chardan NexTech Acquisition 2 (DFLIW) | 431.6% |
Rigetti Computing Inc Warrants (RGTIW) | 363.38% |
Invivyd (IVVD) | 274.47% |
ATAI Life Sciences (ATAI) | 272.26% |
Robinhood Markets (HOOD) | 260.56% |
Rapid Micro Biosystems (RPID) | 252.75% |
Cipher Mining (CIFR) | 250.62% |
Society Pass (SOPA) | 244.06% |
Solid Power (SLDP) | 198.98% |
Gold Royalty (GROY) | 195.08% |
Compass Therapeutics (CMPX) | 182.67% |
Immuneering (IMRX) | 178.64% |
Rigetti Computing (RGTI) | 172.12% |
Nixxy (NIXXW) | 170.95% |
